Literature DB >> 14767007

Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro.

Rosemary Masterson1, Tim D Hewitson, Kristen Kelynack, Marina Martic, Laura Parry, Ross Bathgate, Ian Darby, Gavin Becker.   

Abstract

BACKGROUND: Renal fibroblasts are important effector cells in tubulointerstitial fibrosis, with experimental antifibrotic strategies focusing on the functional down-regulation of these cells. Several experimental models of fibrosis have provided evidence for the effectiveness of the polypeptide hormone relaxin as a potential antifibrotic agent. This study was conducted to further elucidate the antifibrotic mechanisms of relaxin on renal fibroblasts in vitro.
METHODS: Rat cortical fibroblasts were obtained from outgrowth culture of renal tissue isolated from kidneys 3 days post-unilateral ureteric obstruction and constituted 100% of cells studied. A relaxin radio-receptor assay was used to establish binding of relaxin to renal fibroblasts in vitro. Functional studies then examined the effects of H2 relaxin (0, 1, 10 and 100 ng/ml) on fibroblast kinetics, expression of alpha-smooth muscle actin (alpha-SMA), total collagen synthesis, collagenase production and collagen-I lattice contraction. CTGF mRNA expression was also measured by northern analysis.
RESULTS: H2 relaxin bound with high affinity to rat renal fibroblasts, but receptor numbers were low. Consistent with its previously reported bimodal effect, transforming growth factor (TGF-beta 1) reduced fibroblast proliferation, an effect abrogated by H2 relaxin. Fibroblasts exposed to H2 relaxin (100 ng/ml) for 24 h demonstrated decreased immunostaining for alpha-SMA and reduced alpha-SMA protein expression compared with controls. There was a trend for a relaxin-mediated reduction in total collagen synthesis and alpha 1(I) mRNA expression with large dose-related increases in collagenase protein expression being observed. TGF-beta 1-stimulated collagen-I lattice contraction was significantly inhibited following co-incubation with 100 ng/ml relaxin. Incremental doses of H2 relaxin had no significant effect on CTGF mRNA expression.
CONCLUSIONS: The findings of this study suggest that the antifibrotic effects of relaxin involve down-regulation of fibroblast activity, increase in collagenase synthesis and restructuring of collagen-I lattices, which are consistent with its known physiological role of matrix remodelling. Although there appears to be an interaction between TGF-beta 1 and H2 relaxin, this does not appear to involve a reduction in CTGF mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14767007     DOI: 10.1093/ndt/gfg598

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

Review 1.  Immune and inflammatory role in renal disease.

Authors:  John D Imig; Michael J Ryan
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

Review 2.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 3.  Relaxin: antifibrotic properties and effects in models of disease.

Authors:  Chrishan S Samuel
Journal:  Clin Med Res       Date:  2005-11

Review 4.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

5.  The minimal active structure of human relaxin-2.

Authors:  Mohammed Akhter Hossain; K Johan Rosengren; Chrishan S Samuel; Fazel Shabanpoor; Linda J Chan; Ross A D Bathgate; John D Wade
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

6.  Relaxin regulates myofibroblast contractility and protects against lung fibrosis.

Authors:  Xiangwei Huang; Ying Gai; Naiheng Yang; Baogen Lu; Chrishan S Samuel; Victor J Thannickal; Yong Zhou
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

Review 7.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

8.  Relaxin signaling activates peroxisome proliferator-activated receptor gamma.

Authors:  Sudhir Singh; Robert G Bennett
Journal:  Mol Cell Endocrinol       Date:  2009-08-25       Impact factor: 4.102

9.  Relaxin decreases the severity of established hepatic fibrosis in mice.

Authors:  Robert G Bennett; Dean G Heimann; Sudhir Singh; Ronda L Simpson; Dean J Tuma
Journal:  Liver Int       Date:  2013-07-21       Impact factor: 5.828

Review 10.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.